Literature DB >> 8957091

Restoration of the transcription activation function to mutant p53 in human cancer cells.

P Abarzúa1, J E LoSardo, M L Gubler, R Spathis, Y A Lu, A Felix, A Neri.   

Abstract

The p53 tumor suppressor gene product is a sequence-specific transcription activator frequently mutated in a variety of human malignancies. Typically, tumor-derived p53 missense mutants are defective in DNA binding and this is likely to result in a failure to active p53-regulated genes. Hence, restoring function to mutant p53 represents an attractive target to develop a novel cancer chemotherapeutic agent. We now show that a small chemically modified peptide derived from p53 restores sequence-specific DNA binding to a subset of p53 mutants. Moreover, when microinjected into human colon carcinoma cells this peptide restores the transcription activation function to endogenous mutant p53 protein. This is the first example showing that a small peptide molecule can reverse the effect of several inactivating missense mutations and restore protein function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957091

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants.

Authors:  Assaf Friedler; Lars O Hansson; Dmitry B Veprintsev; Stefan M V Freund; Thomas M Rippin; Penka V Nikolova; Mark R Proctor; Stefan Rüdiger; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.

Authors:  Siddharth Singh; Manoj Kumar; Sanjeev Kumar; Shrinka Sen; Pawan Upadhyay; Sayan Bhattacharjee; Naveen M; Vivek Singh Tomar; Siddhartha Roy; Amit Dutt; Tapas K Kundu
Journal:  J Biol Chem       Date:  2019-07-31       Impact factor: 5.157

3.  Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation.

Authors:  M E Anderson; B Woelker; M Reed; P Wang; P Tegtmeyer
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

4.  Identification of an additional negative regulatory region for p53 sequence-specific DNA binding.

Authors:  B F Müller-Tiemann; T D Halazonetis; J J Elting
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Therapeutic strategies for head and neck cancer based on p53 status.

Authors:  Ichiro Ota; Noritomo Okamoto; Katsunari Yane; Akihisa Takahashi; Takashi Masui; Hiroshi Hosoi; Takeo Ohnishi
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

6.  Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.

Authors:  G Selivanova; L Ryabchenko; E Jansson; V Iotsova; K G Wiman
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

7.  Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice.

Authors:  Chinthalapally V Rao; Malisetty V Swamy; Jagan M R Patlolla; Levy Kopelovich
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 8.  New p53-based anti-cancer therapeutic strategies.

Authors:  K G Wiman
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

9.  Mechanism of DNA-binding loss upon single-point mutation in p53.

Authors:  Jon D Wright; Carmay Lim
Journal:  J Biosci       Date:  2007-08       Impact factor: 1.826

10.  Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.

Authors:  Chinthalapally V Rao; Vernon E Steele; Malisetty V Swamy; Jagan M R Patlolla; Suresh Guruswamy; Levy Kopelovich
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.